Invivyd Appoints Chairman Marc W. Elia as CEO Ahead of VYD2311 Phase 3 DECLARATION and LIBERTY COVID Antibody Readouts
Invivyd (NASDAQ: IVVD, Waltham, Massachusetts biopharma focused on serious viral infectious diseases) announced Tuesday September 1, 2026 that the Board of Directors appointed Chairman Marc W. Elia as Chief Executive Officer effective August 30, 2026. Elia has led Invivyd's corporate and scientific strategy since joining the board in 2022 and will serve as Chairman and CEO going forward at an annual base salary of $750,000. The board also named Ajay Royan Lead Independent Director and added Ian Sheffield as an independent director. The leadership transition is timed to Phase 3 readouts for VYD2311, an investigational anti-SARS-CoV-2 monoclonal antibody, in the DECLARATION and LIBERTY studies — both expected in the coming weeks. Invivyd's Pemgarda (pemivibart, the previous-generation SARS-CoV-2 antibody for pre-exposure prophylaxis in immunocompromised adults) received Emergency Use Authorization in March 2024 and remains the company's primary commercial product. A DECLARATION/LIBERTY win would extend the pre-exposure prophylaxis franchise and provide the commercial anchor for a broader antibody-plus-vaccine COVID pipeline.